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Abstract
Aims/hypothesis Excessive weight is a risk factor for type 2 diabetes, but its role in the promotion of autoimmune diabetes is not
clear. We investigated the risk of latent autoimmune diabetes in adults (LADA) in relation to overweight/obesity in two large
population-based studies.
Methods Analyses were based on incident cases of LADA (n = 425) and type 2 diabetes (n = 1420), and 1704 randomly selected
control participants from a Swedish case–control study and prospective data from the Norwegian HUNT Study including 147
people with LADA and 1,012,957 person-years of follow-up (1984–2008). We present adjusted ORs and HRs with 95% CI.
Results In the Swedish data, obesity was associated with an increased risk of LADA (OR 2.93, 95% CI 2.17, 3.97), which was
even stronger for type 2 diabetes (OR 18.88, 95% CI 14.29, 24.94). The association was stronger in LADA with low GAD
antibody (GADA; <median) (OR 4.25; 95% CI 2.76, 6.52) but present also in LADAwith high GADA (OR 2.14; 95% CI 1.42,
3.24). In the Swedish data, obese vs normal weight LADA patients had lower GADA levels, better beta cell function, and were
more likely to have low-risk HLA-genotypes. The combination of overweight and family history of diabetes (FHD) conferred an
OR of 4.57 (95% CI 3.27, 6.39) for LADA and 24.51 (95% CI 17.82, 33.71) for type 2 diabetes. Prospective data from HUNT
indicated even stronger associations; HR for LADAwas 6.07 (95% CI 3.76, 9.78) for obesity and 7.45 (95% CI 4.02, 13.82) for
overweight and FHD.
Conclusions/interpretation Overweight/obesity is associated with increased risk of LADA, particularly when in combination
with FHD. These findings support the hypothesis that, even in the presence of autoimmunity, factors linked to insulin resistance,
such as excessive weight, could promote onset of diabetes.
Keywords ANDIS . ANDiU . Body mass index . Case–control study . ESTRID . HUNT Study . LADA . Latent autoimmune
diabetes in adults . Prospective study . Type 2 diabetes
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-018-4596-0) contains peer-reviewed but
unedited supplementary material, which is available to authorised users.
* Rebecka Hjort
rebecka.hjort@ki.se
1 Unit of Epidemiology, Institute of Environmental Medicine,
Karolinska Institutet, Box 210, 171 77 Stockholm, Sweden
2 Department of Clinical Sciences inMalmö, Clinical Research Centre,
Lund University, Malmö, Sweden
3 Department of Medical Sciences, Uppsala University,
Uppsala, Sweden
4 Department of Clinical and Molecular Medicine, NTNU, Norwegian
University of Science and Technology, Trondheim, Norway
5 Department of Endocrinology, St Olavs Hospital, Trondheim
University Hospital, Trondheim, Norway
6 Finnish Institute of Molecular Medicine, University of Helsinki,
Helsinki, Finland
7 Department of Public Health and Caring Sciences, Uppsala
University, Uppsala, Sweden
8 Division of Endocrinology, Abdominal Center, Helsinki University
Hospital, Research Program for Diabetes and Obesity, University of
Helsinki, Helsinki, Finland
9 Folkhälsan Research Center, Helsinki, Finland
10 K.G. Jebsen Center for Genetic Epidemiology, Department of Public





ANDIS All New Diabetics In Scania
ANDiU All New Diabetics in Uppsala County
ESTRID Epidemiological Study of Risk Factors
for LADA and Type 2 diabetes
FHD Family history of diabetes
GADA GAD antibody
HUNT Study Nord-Trøndelag Health Study
LADA Latent autoimmune diabetes in adults
LADAhigh LADA group with high median GADA




Overweight and obesity are major risk factors for type 2 dia-
betes [1], and the association between excessive weight and
insulin resistance is well known. Several mediating pathways
have been proposed, including ectopic lipid accumulation and
lipotoxicity, and the release of proinflammatory cytokines
from visceral fat tissue [2].
Type 1 diabetes has been viewed as a non-obese form of
diabetes, but this was challenged by the accelerator hypothesis
[3], which proposes that obesity accelerates disease onset and,
further, that insulin resistance is a common underlying feature
of all types of diabetes [3]. Insulin resistance has also been
postulated to be an independent risk factor for type 1 diabetes
[4, 5]. Adiposity could potentially affect risk via beta cell
autoimmunity; adipokines, which are secreted from exces-
sive fat tissue, have been shown to be involved in various
immune-mediating processes [6]. Subsequent prospective
studies have reported a twofold increased risk of type 1
diabetes in obese children [7] and obese adults [8], while
others find no association [9]. An association is further
supported by the coincident increases in childhood obesi-
ty and type 1 diabetes incidence [10, 11].
Latent autoimmune diabetes in adults (LADA) is an auto-
immune form of diabetes with features of type 2 diabetes,
including adult onset and insulin resistance [12].
Autoimmunity is typically less pronounced than in type 1
diabetes, which implies that insulin resistance, increasing the
beta cell demand, may play a key role in the promotion of
LADA. In line with this, data from cross-sectional studies
[13–19] suggest that individuals with LADA tend to have
higher BMI than those with type 1 diabetes, but lower than
those with type 2 diabetes. Interestingly, the clinical pheno-
type of LADA is known to vary by degree of autoimmunity,
with less autoimmune individuals being more type 2-like.
Hence, the role of overweight in the development of LADA
may depend on the severity of the underlying autoimmune
process. Only one prospective study based on 11 years
follow-up of the Norwegian Nord-Trøndelag Health Study
(HUNT Study) estimated the risk of LADA in relation to
overweight/obesity [20]. This study was based on only 81
individuals; hence, the influence of excessive weight on more
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and confounding control was limited. Other aspects that re-
main to be addressed include interaction between overweight
and family history of diabetes (FHD), which is a strong indi-
cator of type 2 diabetes risk [21], whether the shape of asso-
ciation is linear or not, and the preventive potential of over-
weight in the aetiology of LADA.
Our aim was to describe the association between over-
weight and obesity and LADA compared with type 2 diabetes,
taking into account degree of autoimmunity and potential in-
teraction with FHD. We used updated prospective data from
the HUNT Study, including 22 years of follow-up, and newly




Study population and design The Epidemiological Study of
Risk Factors for LADA and Type 2 Diabetes (ESTRID) is an
ongoing population-based case–control study [22]. In short,
ESTRID is a substudy of All New Diabetics In Scania
(ANDIS; http://andis.ludc.med.lu.se), an extensive diabetes
study aimed at characterising clinical and genetic factors in
incident cases in Scania. Since 2010, we have recruited all
incident cases of LADA and a random sample of those with
type 2 diabetes (four for every one person with LADA) from
ANDIS. Since 2012, we have also included individuals from
ANDiU (All New Diabetics in Uppsala County; www.andiu.
se/), a sister study to ANDIS. Control participants (six for
every one person with LADA [≥35 years of age]) without
diabetes are randomly selected from the national population
register and matched to the case for county and time of
recruitment (incident density sampling) [23].
The analytical sample for the present study consisted of all
individuals recruited until July 2016 and with complete infor-
mation on BMI, age, sex, FHD, physical activity and smoking
(98.2% of the study sample): 425 individuals with LADA,
1420 individuals with type 2 diabetes and 1704 control par-
ticipants (95% of participants came from Scania and 5% came
from Uppsala). The response rate was 80% for the individuals
with LADA and type 2 diabetes and 64% for control partici-
pants. ESTRID was approved by the ethical review board in
Stockholm and all participants gave written informed consent.
Case definition and biochemical analyses At diagnosis, blood
samples were collected from all individuals and analysed for
GAD antibody (GADA) in serum using ELISA (RSR,
Cardiff, UK). At the cut-off level for positivity (10 U/ml),
sensitivity was 84% and specificity 98% [24]. Fasting C-
peptide was assessed in plasma using IMMULITE 2000
(Siemens Healthcare Diagnostics, Llanberis, UK) or Cobas e
601 (Roche Diagnostics, Mannheim, Germany).
Individuals with LADA had diagnosis ≥35 years of
age, were GADA positive (≥10 U/ml) and had C-
peptide levels above the lower limit for the normal range
≥0.2 nmol/l (IMMULITE) or ≥0.3 nmol/l (Cobas e 601).
Type 2 diabetes was defined as onset ≥35 years of age,
GADA negativity (<10 U/ml) and C-peptide levels
>0.6 nmol/l (IMMULITE) or ≥0.72 nmol/l (Cobas e
601). DNA was analysed using iPLEX Gold technology
(Sequenom Laboratories, San Diego, CA, USA). Three
SNPs in the MHC region (rs3104413, rs2854275,
rs9273363) were combined to identify high- and low-
risk HLA-DR and HLA-DQ genotypes associated with
autoimmunity [25], according to previously used
methods [26]. Missing genotypes were completed using
imputed data from an ANDIS subset genotyped on
Infinium CoreExome v1.1 (Illumina, San Diego, CA,
USA), imputed based on the Haplotype Reference
Consortium (http://www.haplotype-reference-consortium.
org/; version r1.1 2016) reference panel. HOMA was
used to estimate insulin resistance, insulin sensitivity
and beta cell function based on the relationship
between fasting values of C-peptide and plasma glucose
[27]. No genetic or clinical information was available for
the control participants.
BMI and covariates Case and control participants answered an
extensive questionnaire at inclusion. For those with LADA or
type 2 diabetes, this was done as close to diagnosis as possible
(median 5 months), with careful instructions to report lifestyle
as it was prior to diagnosis. Current BMI was based on self-
reported weight and height, which shows high correlation (r =
0.92) with BMI based on measurements taken at diagnosis
(those with LADA or type 2 diabetes). BMI was categorised
as: normal weight <25 kg/m2, overweight 25–29.9 kg/m2 and
obese ≥30 kg/m2 (WHO). BMI at age 20 years was calculated
based on self-reported information on weight at age 20 years
(80.4% of the study sample could recall this information) and
current height. FHD was obtained from questions on diabetes
in first-degree relatives (mother, father, sisters, brothers and
children). Relatives with onset <40 years of age and with
insulin treatment were considered to have type 1 diabetes,
otherwise they were judged to have type 2 diabetes. Physical
activity level (sedentary, low, moderate or high activity) was
assessed from validated questions [28] on leisure time activity.
Individuals were categorised based on highest achieved edu-
cation (primary school, upper secondary school, university)
and through detailed questions on lifetime smoking as never,
former or current smokers. Alcohol habits were categorised
into four groups (ranging from abstainers to high consumers),
based on questions on amount and frequency of wine, beer
and liquor intake.
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The HUNT Study
Study population and design In the county of Nord-
Trøndelag, all residents ≥20 years of age were invited to
participate in the HUNT Study on three occasions be-
tween 1984 and 2008: HUNT1 (1984–1986), HUNT2
(1995–1997) and HUNT3 (2006–2008) [29]. At each sur-
vey, data for participants were gathered from clinical ex-
aminations, anthropometrical measurements and compre-
hensive questionnaires with questions on general health,
FHD and lifestyle. Analyses were based on all individuals
who participated in at least two surveys, were free of
diabetes at baseline and with complete information on
BMI, age, sex, FHD, physical activity and smoking (n =
56,549). The HUNT Study was approved by the
Norwegian Data Protection Authority and the Regional
Committee for Medical and Health Research Ethics and
participants gave informed consent.
Case definition Incident cases were identified by self-report
of diabetes and age at diagnosis. This self-report has high
validity when compared with medical records [30].
Individuals with self-reported diabetes at HUNT2 or
HUNT3 were invited for fasting blood sampling. Level of
GADA, reported as an index value in relation to standard
serum, was measured in fasting serum samples by immu-
noprecipitation radioligand assay using translation-labelled
[3H]GAD65 as a labelled reagent (Novo Nordisk,
Bagsværd, Denmark). The sensitivity and specificity of
the assay were 0.64 and 1.00 at cut-off ≥0.08 [31].
Individuals were classified as having LADA if they were
aged ≥35 years at diagnosis and GADA positive (≥0.08
antibody index [WHO; ≥43 U/ml]; n = 147). This implies
that we have included individuals with adult-onset type 1
diabetes. The proportion accounted for by these individ-
uals is likely to be small as, when we used information
on treatment (available for 83.5% of the total study popu-
lation), 82.7% (n = 105) of those with GADA positivity did
not report insulin treatment during the year of diagnosis.
For convenience, this group will be referred to as LADA;
subanalysis based on a stricter definition of LADA (no
insulin treatment) has been conducted. Individuals with
type 2 diabetes were ≥35 years of age and GADA negative
(<43 U/ml; n = 2002). C-peptide (nmol/l) (not from time of
diagnosis) was measured in fasting serum samples and
analysed by RIA (Diagnostic Systems Laboratories,
Webster, TX, USA). HOMA indicators were calculated
based on fasting C-peptide and glucose as described above.
BMI, WHR and covariates BMI was calculated from weight
and height measured at the clinical examination. Waist and
hip circumference (only available from baseline in HUNT2)
and height were used to calculate WHR and waist-to-height
ratio (WHtR). The measures were dichotomised according to
previously used risk levels [32]. Those with self-reported
FHD in any of the three surveys were considered to have
FHD. Baseline information (HUNT1 or HUNT2) was used
to classify individuals according to leisure-time physical ac-
tivity (sedentary, low, moderate or high activity), highest-
attained education (primary school, upper secondary school,
university), smoking status (never, former, current) and alco-
hol consumption (abstainers, low, moderate or high
consumers).
Statistical analyses
Baseline characteristics were expressed as proportions, means
(SD), or medians (interquartile range [IQR]). Two-sided
p values were calculated using χ2 (proportions), Student’s t
(means) and Kruskal–Wallis (medians). ORs with 95% CIs
were calculated by conditional logistic regression for case–
control data (ESTRID) and HRs with CIs were calculated by
proportional Cox regression for prospective data (HUNT). As
control participants were sampled with an incidence density
method, the ORs can be interpreted as incidence rate ratios
[23]. In HUNT, person-years were calculated from age at
study entry until age at onset of diabetes, death or age at end
of the follow-up (either HUNT2 in 1997 or HUNT3 in 2008),
whichever came first. Time-dependent variables were used,
hence for individuals participating both in HUNT1 and
HUNT2, information on exposure and covariates was updated
at the second time of participation.
To explore the relationship between BMI and diabetes, we
used restricted cubic spline models to allow fitting of a
smooth curve without assumption about linearity [33],
modelled with five knots at equally spaced percentiles of
the marginal distribution of BMI. BMI was truncated below
15 kg/m2 and above 45 kg/m2 to remove the influence of
outliers. The relationship between BMI and insulin resistance
(loge HOMA-IR) and loge GADA was assessed by linear
regression. Interaction was defined as departure from additiv-
ity of effects [34] and tested by calculating attributable pro-
portion due to interaction together with 95% CI [35].
Population-attributable risk (PAR) was calculated with the
formula: p(1-[1/RR]) where p is the prevalence (%) of the
risk factor of interest among cases and RR is the adjusted
OR (ESTRID) or HR (HUNT) [36]. All analyses were ad-
justed for by age (underlying timescale in the Cox model),
sex, first-degree FHD, physical activity and smoking.
Adjustment for alcohol intake and education had minor ef-
fects on the risk estimates (<10% change) and were not in-
cluded in the final model. Individuals with LADAwere strat-
ified by median GADA level (196.0 U/ml [ESTRID] and
134.4 U/ml [HUNT]), referred to in the paper as LADAlow
and LADAhigh. Statistical Analysis Software (SAS) 9.4 (SAS
Institute, Cary, NC, USA) or Stata Statistical Software 14
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(StataCorp, College Station, TX, USA) (for calculating
splines) were used for the statistical analyses.
Results
Characteristics
In both populations, individuals with LADAwere younger at
diagnosis, had lower C-peptide concentrations and were more
often on insulin treatment than individuals with type 2 diabe-
tes (Table 1). In ESTRID, individuals with LADA had a lower
level of insulin resistance (HOMA) and had a higher propor-
tion of high-risk HLA genotypes and FHD of type 1 diabetes.
Individuals with LADA were leaner than those with type 2
diabetes, whereas in HUNT, there was no corresponding dif-
ference (Table 1). However, mean WHR was higher in indi-
viduals with type 2 diabetes. Comparing LADAlow and
LADAhigh, the former group displayed higher concentrations
of C-peptide and better beta cell function but a higher level of
insulin resistance (ESM Table 1).
Overweight, obesity and LADA
In ESTRID, the OR for LADAwas 2.93 (95% CI 2.17, 3.97)
among obese compared with normal weight participants
(Table 2). The association seemed stronger in LADAlow (OR
4.25, 95% CI 2.76, 6.52) than in LADAhigh (OR 2.14, 95% CI
1.42, 3.24). Prospective data fromHUNT indicated similar but
stronger associations; the HR associatedwith obesity was 6.07
(95% CI 3.76, 9.78) for LADA, 10.00 (95% CI 4.34, 23.03)
for LADAlow and 4.58 (95% CI 2.49, 8.45) for LADAhigh.
Abdominal obesity (HUNT) increased the risk of LADA near-
ly twofold (HR 1.89, 95% CI 1.03, 3.46) measured withWHR
and threefold (HR 3.14, 95% CI 1.56, 6.30) measured with
WHtR (Table 2) (HUNT). Results from HUNT were similar
with a stricter definition of LADA (no insulin treatment); HR
was 6.63 (95% CI 3.67, 12.00) for obesity. LADA was also
associated with weight change over time; for every unit in-
crease in BMI since age 20 years, OR increased by 10% (OR
1.10, 95% CI 1.07, 1.14) (Table 2). The association between
BMI and LADA was similar in men and women (ESM
Tables 2 and 3).
Table 1 Characteristics of study participants
Characteristics HUNT ESTRID







Number of individuals 54,440 2002 147 1704 1420 425
Women, % 53.2 47.3 51.7 0.3028 51.9 39.2 45.7 0.0181
Age at diagnosis, years (at inclusion for
control participants), mean (SD)b
– 60.9 (10.9) 59.9 (11.1) 0.3039 58.4 (13.5) 63.2 (10.3) 59.0 (12.3) <0.0001
Age, years, at baseline (HUNT), mean (SD) 48.3 (15.8) 54.8 (11.0) 54.4 (11.2) 0.6928 – – – –
BMI, kg/m2, mean (SD) 25.5 (3.8) 29.8 (4.5) 29.2 (4.9) 0.1704 25.9 (4.2) 31.2 (5.4) 28.1 (5.3) <0.0001
WHR, mean (SD)c 0.84 (0.08) 0.90 (0.07) 0.87 (0.07) 0.0260 – – – –
Any first-degree FHD, % 24.2 57.1 48.3 0.0379 24.4 49.8 45.2 0.0951
FHD-T2D, % – – – – 22.65 47.61 36.71 <0.0001
FHD-T1D, % – – – – 2.58 5.00 11.29 <0.0001
With insulin treatment, % – 3.4 17.3 <0.0001 – 5.9 41.2 <0.0001
C-peptide, nmol/l, median (IQR)d – 0.86 (0.60) 0.57 (0.78) <0.0001 – 1.20 (0.65) 0.69 (0.67) <0.0001
GADA, U/ml, median (IQR) – – 134.4 (521.4) – – – 196.0 (224.0) –
HOMA-IR, median (IQR)d – 2.20 (1.60) 2.10 (1.70) 0.1119 – 3.50 (2.20) 2.70 (2.60) <0.0001
HOMA-β, median (IQR)d – 64.5 (49.2) 59.0 (50.8) 0.4109 – 68.1 (49.8) 37.8 (53.6) <0.0001
HOMA-S, median (IQR)d – 45.2 (30.7) 47.2 (49.0) 0.1263 – 28.2 (16.4) 36.9 (32.8) <0.0001
High-risk HLA, %e – – – – – 31.1 61.4 <0.0001
Low-risk HLA, %e – – – – – 45.0 21.9 <0.0001
a p for difference between LADA and type 2 diabetes
bMedian 5 months after diabetes diagnosis for cases in ESTRID
c Information only available from baseline at HUNT2 (1995–1997)
d Clinical information was available for 92.6% of the individuals in ESTRID (LADA n = 394, type 2 diabetes n = 1315) and 70.7% of participants in
HUNT (LADA n = 118, type 2 diabetes n = 1401)
e Genetic information was available for 90.4% of the individuals in ESTRID (LADA n = 389, type 2 diabetes n = 1278)
T1D, type 1 diabetes; T2D, type 2 diabetes







































































































































































































































































































































































































































































































































































































































































































































































































































































































1338 Diabetologia (2018) 61:1333–1343
Overweight, obesity and type 2 diabetes
The association between overweight/obesity and type 2 dia-
betes was stronger than for LADA, obesity was associated
with OR of 18.88 (95% CI 14.29, 24.94) in ESTRID and
HR was 9.83 (95% CI 8.49, 11.38) in HUNT (Table 2).
Abdominal obesity was associated with type 2 diabetes, HR
3.57 (95% CI 3.11, 4.09; WHR) and HR 5.08 (95% CI 4.21,
6.12; WHtR). For every BMI unit increase since age 20 years,
OR for type 2 diabetes increased by 27% (OR 1.27, 95% CI
1.23, 1.30) (ESTRID).
Restricted cubic spline analyses
Restricted cubic spline models were used to explore the po-
tential linear relationship between BMI and diabetes (Fig. 1).
For type 2 diabetes, a strong linear association was seen over
the whole range of BMI with a slight levelling off above BMI
27 kg/m2. For LADA, a linear pattern was less pronounced
with a tendency of a U-shaped relationship; however, above
BMI 24 kg/m2 the OR increased exponentially. A similar
shape was seen for both LADAhigh and LADAlow, but with
an apparently steeper line for the latter group.
Interaction between overweight and FHD
Individuals with a combination of FHD and overweight had
OR 4.57 (95% CI 3.27, 6.39) for LADA and 24.51 (95% CI
17.82, 33.71) for type 2 diabetes (ESTRID). Corresponding
HR estimates in HUNT were 7.45 (95% CI 4.02, 13.82) and
17.52 (95%CI 14.17, 21.66), respectively (Fig. 2). Interaction
between FHD and overweight was seen for type 2 diabetes
(attributable proportion 0.57, 95% CI 0.49, 0.66), but not for
LADA (attributable proportion 0.06 95% CI −0.25, 0.37) in
ESTRID. Results in HUNT were similar for type 2 diabetes
(attributable proportion 0.58, 95% CI 0.53, 0.63), but stronger
for LADA (attributable proportion 0.37, 95% CI 0.10, 0.64).
Population-attributable risk
Calculations of PAR indicated that 31.0% (95% CI 20.2%,
39.5%) of all individuals with LADA and 81.8% (95% CI
78.7%, 84.1%) of all individuals with type 2 diabetes in the
ESTRID study can be ascribed to overweight/obesity.
Corresponding proportions in HUNT were 56.4% (95% CI
42.3%, 65.5%) (LADA) and 69.9% (95% CI 67.2%, 72.2%)
(type 2 diabetes).
Characteristics of individuals with LADA by category
of BMI
In both populations, obese vs normal weight individuals with
LADA had greater insulin production (C-peptide) and were
less often receiving insulin treatment (ESMTables 4 and 5). In
ESTRID, obese individuals also had lower GADA levels, bet-
ter beta cell function (HOMA) and a higher level of insulin
Fig. 1 ORs with 95% CIs for (a)
LADA, (b) type 2 diabetes, (c)
LADAhigh, and (d) LADAlow by
BMI (kg/m2) fitted with restricted
cubic splines using data from
ESTRID 2010–2016. The
reference value is BMI 23 kg/m2
and models were adjusted for age,
sex, FHD, physical activity level
and smoking. Black solid lines
represent the spline line, long
dashed lines represent the 95%
CIs of the spline line and the red
dotted lines represent the linear
line. The histogram at the bottom
of each figure part represents the
distribution of BMI in the study
population. The left y-axes are on
a loge scale
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resistance (HOMA). Similar tendencies were seen in HUNT.
However, the differences were not significant (ESM Tables 4
and 5). In ESTRID, obese individuals with LADAwere also
more likely to have low-risk HLA genotypes and tended to
less commonly have first-degree relatives with type 1 diabe-
tes. BMI was positively associated with HOMA-IR (2.2%
increase, p = 0.0002) and inversely associated with GADA
(5.1% decrease, p < 0.0001) per BMI unit. In HUNT, results
were similar for HOMA-IR (3.8% increase, p = 0.0077) but
weaker for GADA (0.8% decrease, p = 0.6773).
Discussion
Our findings using data from two large population-based stud-
ies indicate that overweight and obesity are associated with an
increased risk of LADA and that the risk is highest in individ-
uals with a combination of overweight and FHD. The associ-
ation with obesity seemed strongest in LADA with low
GADA, but was apparent also in LADAwith higher GADA
levels. The results indicate that LADA in 31–56% of individ-
uals could be attributed to overweight/obesity, compared with
70–82% of all those with type 2 diabetes.
These findings fit with those of previous cross-sectional
studies, which indicated that individuals with LADA tend to
be obese but leaner than those with type 2 diabetes [13–19]
and with previous reports of LADA being characterised by
insulin resistance, but to a lesser extent than type 2 diabetes
[12]. One previous study found that a majority of individuals
with LADA have a lean phenotype [37]. One explanation of
this somewhat conflicting result may be the use of a different
age criterion (>25 years), as younger age at onset tends to be
associatedwith a more type-1-like phenotype [38]. In contrast,
the large multicentre ADOPT study found that participants
with LADA and type 2 diabetes were equally overweight/
obese [39]. In this study, however, GADA was measured in
individuals with prevalent diabetes without insulin treatment
within the first 3 years of diagnosis. As such, these individuals
with LADAwere likely to have a more type-2-like phenotype.
These findings highlight the heterogeneous nature of LADA
and the need for a unified definition.
BMI was positively associated with insulin resistance in
LADA, suggesting that this is an underlying pathway. In con-
trast, there was nothing to suggest that excessive weight
would influence autoimmunity per se; there was an inverse
association between BMI and GADA level similar to a previ-
ous report [25]. Reports of type 1 diabetes in children are in
keeping with our data; obesity has been associated with insu-
lin resistance [40], but not with autoimmunity, irrespective of
number and type of diabetes antibodies in the study partici-
pants [41]. Our findings fit with the accelerator hypothesis [3],
which proposes that insulin resistance plays a role in promot-
ing autoimmune diabetes by increasing the insulin demand—
this may accelerate disease onset in individuals with an ongo-
ing autoimmune process. In the case of mild autoimmunity,
one can hypothesise that factors related to insulin resistance
are more important for progression to overt diabetes. This
could explain why we found a stronger association between
high BMI and less autoimmune LADA and also why the
phenotype of the obese individuals with LADA compared
with those with normal weight, in line with previous reports
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Fig. 2 ORs for (a) LADA and (b)
type 2 diabetes in ESTRID. HRs
for (c) LADA and (d) type 2
diabetes in HUNT by
combinations of overweight/
obesity (BMI ≥ 25 kg/m2) and
FHD. The reference is normal
weight (BMI < 25 kg/m2) and no
FHD. The y-axis is on the log10
scale and error bars are 95% CI
1340 Diabetologia (2018) 61:1333–1343
levels, better beta cell function and a higher level of insulin
resistance. There was a tendency towards a U-shaped relation-
ship between LADA and BMI. If not occurring by chance, it
may reflect the weight loss often seen in individuals with type
1 diabetes prior to diagnosis as a consequence of insufficient
insulin production.
The association between BMI and LADAwas stronger in
the prospective data from HUNT, where BMI was assessed
several years prior to diagnosis, than in the Swedish case–
control data, where BMI was assessed at time of diagnosis.
It is possible that the baseline measurements in HUNT reflect
a more aetiologically relevant exposure window. Self-reported
weight in the case–control study may also have contributed to
dilution of associations. On the other hand, the association
between type 2 diabetes and BMI was stronger in ESTRID.
Another explanation may be that the LADA populations differ
in either genetic or unmeasured phenotypical factors.
We confirm the strong association previously reported of
overweight and obesity with type 2 diabetes [1]. In addition,
we confirm that the combination of overweight and FHD dra-
matically increases the risk of type 2 diabetes [21] and show,
for the first time, that the risk of LADA increases substantially
in individuals with FHD and overweight, although the effect is
not as pronounced as for type 2 diabetes. Unfortunately, the
numbers did not allow us to explore interaction with BMI
separately in individuals with a family history of type 1 diabe-
tes vs those with a family history of type 2 diabetes. We have
previously shown that LADA is associated with a family his-
tory of type 2 diabetes, but even more so with a family history
of type 1 diabetes [42], which is in line with genetic studies
showing a strong link between LADA and HLA genotypes
associatedwith type 1 diabetes [12]. Together with the findings
of present study, this supports the idea that LADA is a hybrid
form of diabetes promoted by genes associated with autoim-
munity and lifestyle factors inducing insulin resistance.
Strengths and limitations
The strengths of this study include the large number of inci-
dent cases, detailed information on potential confounders and
the use of two well-defined population-based studies. The
specificity of the GADA assessment was high, but it is possi-
ble that some participants with type 2 diabetes were
misclassified as LADA, i.e. were false positives. This may
contribute to an association with BMI, especially for
LADAlow. It has also been suggested that individuals with
LADA and low GADA are actually false positives [43].
However, we found that these individuals differ from those
with type 2 diabetes in several clinical characteristics. Also,
previous studies in the HUNT Study indicate a real impact of
even low and transient levels of GADA, e.g. individuals with
low GADA display lower fasting C-peptide levels than indi-
viduals with type 2 diabetes [44]. Still, the importance of
GADA positivity for disease progression in very obese indi-
viduals with low GADA levels is unclear. The sensitivity of
the method and the use of only one autoantibody imply that
some individuals with LADAwere classified as GADA neg-
ative, i.e. as having type 2 diabetes. Importantly, GADA is by
far the most common autoantibody in LADA, present in
~90% of all individuals [45]. In the HUNT Study, some indi-
viduals had GADA measured several years after diagnosis.
Because GADA can disappear after prolonged disease dura-
tion [44], it is possible that some individuals with LADA
therefore appeared GADA negative and were classified as
having type 2 diabetes. Notably, GADA tends to be more
stable in LADA than in type 1 diabetes [12]. Although there
is no unified definition of LADA, the present report is consis-
tent with currently used criteria [12], with the exception of C-
peptide which was used in ESTRID as an indicator of remain-
ing insulin production and can be considered a more objective
measure compared with the frequently used insulin criterion,
i.e. lack of insulin treatment 6–12 months after diagnosis [12].
Estimation of PAR is based on the assumptions of causality
and the absence of measurement errors and bias and should
hence be interpreted with caution. As for generalisability, it
should be noted that PAR is based on the estimated effect size
as well as prevalence of overweight in the population and is,
as such, population specific. The study is based on popula-
tions in Scandinavia, where the incidence of autoimmune di-
abetes is high, and the results may be less generalisable to
areas with lower incidence. Last, assessment on insulin resis-
tance was based on HOMA and even though HOMA has been
validated against the hyperinsulinaemic–euglycemic clamp
with good correlation [46], it is still a crude method.
In conclusion, under the assumption of causality, excessive
weight is a strong contributor to development of LADA and
maintaining a healthy weight should be a priority, especially in
the presence of FHD or autoimmunity. As expected, obese
individuals with LADA had a more type-2-like phenotype,
but overweight/obesity was also associated with more autoim-
mune LADA. These findings support the hypothesis that even
in the presence of autoimmunity, factors linked to insulin re-
sistance such as excessive weight could promote the onset of
diabetes.
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